Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Previous revision
teaching:pharmaceutical-industry-influence [on April 30, 2020]
teaching:pharmaceutical-industry-influence [on June 19, 2020]
Line 50: Line 50:
 ===== Regulatory Capture ===== ===== Regulatory Capture =====
   * [[https://​www.ncbi.nlm.nih.gov/​pubmed/​12433532|Abraham,​ J. (2002). The pharmaceutical industry as a political player. The Lancet, 360(9344), 1498-1502.]]   * [[https://​www.ncbi.nlm.nih.gov/​pubmed/​12433532|Abraham,​ J. (2002). The pharmaceutical industry as a political player. The Lancet, 360(9344), 1498-1502.]]
 +
 +===== Clinical Practice Guidelines =====
 +  * [[https://​www.cmaj.ca/​content/​192/​23/​E617|Elder,​ K., Turner, K. A., Cosgrove, L., Lexchin, J., Shnier, A., Moore, A., ... & Thombs, B. D. (2020). Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ, 192(23), E617-E625.]]
  
 ===== Reform ===== ===== Reform =====
-<​callout>​“is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine."​+<​callout>​“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine."​
 \\ \\ \\ \\
 -- //Dr. Marcia Angell, Drug Companies & Doctors: A Story of Corruption//</​callout>​ -- //Dr. Marcia Angell, Drug Companies & Doctors: A Story of Corruption//</​callout>​